Popular weight-loss drug orlistat may cause severe liver and kidney failure
Washington, December 11 (ANI): Weight-loss drug orlistat, known by the brand names Xenical and Alli, inhibits a key enzyme that may lead to "severe toxicity of internal organs such as the liver and kidney," according to a University of Rhode Island researcher.
The inhibition is irreversible and can be caused by a low level of the drug.
Professor Bingfang Yan's study funded by the National Institutes of Health, also found that the drug alters efficacy of medicines, and particularly limits the effectiveness of some anti-cancer drugs.
Orlistat, which was originally approved by the FDA in 1999 as the prescription drug Exenical, was approved in 2007 as the over-the-counter medication Alli. It has been the most commonly used medicine to treat obesity for more than a decade, Yan said.
"Since it has been available over-the-counter, there has been a drastic increase of toxicity among patients using the drug. It has been linked to severe liver failure, acute pancreatic failure and acute renal (kidney) failure," Yan said.
Yan said orlistat works in the intestinal tract by preventing fat from being absorbed by the body. It is generally accepted that orlistat remains in the intestine and that the body does not absorb it.
"But orlistat is reportedly absorbed, and certainly internal organs such as the liver and kidney are exposed to this drug upon absorption," he said.
The study showed that the drug is a potent inhibitor of carboxylesterase-2, which is a major detoxification enzyme in the liver, kidney and gastrointestinal track.
"When the activity of this enzyme drop in those organs, toxicity increases or the efficacy of some drugs are altered," Yan said.
The enzyme is known to metabolize a wide range of medicines including aspirin and the cancer drugs irinotecan and pentyl carbamate of p-aminobenzyl carbamate of doxazolidine.
"This study shows that orlistat profoundly alters the therapeutic potential of the anti-cancer drugs. In the case of the anti-cancer drugs, it weakens their effectiveness," Yan said.
Prior or co-presence of orlistat with one of the anti-cancer drugs resulted in cancer cells being far more prolific.
"Alli-based interactions can be key factors in the efficacy of medicines," Yan said.
Yan was also interested in Alli's effects on aspirin and its use as a blood thinner. "Aspirin is used to treat blood clots. Yan predicated: "Orlistat would increase the therapeutic potential of aspirin, which may increase the tendency of bleeding."
Part of the research results will be published in the journal, Biochemical Pharmacology, which has the article posted on its website. (ANI)
TIME IS NIGH TO UNITE AGAINST BJP SAYS ALI ANWAR TO NNIS
November 29, 2014 at 1:48 PM
KARISHMA KAPOOR GRACES FINALE OF SHIAMAK DAVARS WINTER FUNK
November 29, 2014 at 1:26 PM
CELEBS GRACE LAUNCH OF GREEK RESTAURANT KIPOS IN MUMBAI
November 29, 2014 at 1:26 PM
WE ARE HIGH ON CONFIDENCE- MADS JUNKER
November 29, 2014 at 1:25 PM
Take extra care of Jharkhand between 13-18 years, choose good govt: PM Modi
November 29, 2014 at 1:13 PM
PM Modi addresses rally in Jamshedpur
November 29, 2014 at 1:12 PM
email@example.comDecember 12, 2012 at 5:23 PM